Brielle Urciuoli

Articles

Persistence and the Quest for Innovation Guided a Radiotherapy Pioneer

May 7th 2018

Herman D. Suit, MD, MSc, PhD, a leader in the field of radiation oncology whose innovations lessened the need for radical surgery and improved outcomes for patients, was honored in the Radiation Oncology category with a 2017 Giants of Cancer Care® award.

Pembrolizumab Continues to Demonstrate Long-Term Efficacy in Melanoma

February 19th 2018

The PD-1 inhibitor pembrolizumab (Keytruda) continues to be a promising frontline immunotherapy option for patients with advanced melanoma.

FDA Warning Links Breast Implants to ALCL

March 29th 2017

Breast implants may increase an individual’s risk of developing anaplastic large cell lymphoma, a recent FDA advisory warned.

Neoadjuvant Therapy Improves Breast Conservation Outlook

March 15th 2017

Debu Tripathy, MD, provided an update on neoadjuvant strategies in HER2-positive breast cancer at the 2017 Miami Breast Cancer Conference.

Study Explores Correlations Among Irregular Menstrual Cycles, PCOS, and Ovarian Cancer Risk

January 27th 2017

Long or irregular menstrual cycles may be a marker of an increased risk for developing certain subtypes of ovarian cancer, according to the results of a recent study.

TKI Sequencing in RCC Will Bring in New Paradigms, Outcomes

November 27th 2016

In the past decade, the addition of tyrosine kinase inhibitors has had a huge impact on the treatment of renal cell carcinoma in the first- and second-line settings. Currently available agents include sorafenib, sunitinib, pazopanib, axitinib, and the recently-added cabozantinib, and lenvatinib.

Using PD-L1 Expression to Determine Lung Cancer Treatments

November 15th 2016

Standard of care for newly diagnosed non-small cell lung cancer is shifting to include PD-L1 expression to determine the appropriate treatment plan, says Matthew D. Hellmann, MD.

Therapeutic Options Expanding for ALK-Rearranged NSCLC

November 13th 2016

The treatment landscape for patients with ALK-rearranged non–small cell lung cancer is changing rapidly, gearing up the potential for more therapeutic options to address the heterogeneity of the mechanism of resistance in this population.

SD-101, Pembrolizumab Combo Well-Tolerated in Early-Stage Melanoma

November 10th 2016

Results from a safety, tolerability, and dose escalation phase Ib/II study involving intratumoral SD-101 and pembrolizumab (Keytruda) have demonstrated that the combination was well-tolerated with no dose-limiting toxicities.

Dabrafenib/Trametinib OS Duration Associated With Number of Metastatic Melanoma Sites

November 9th 2016

The combination of dabrafenib and trametinib continued to demonstrate durable efficacy for patients with BRAF V600E/K-mutant melanoma across patient subgroups in a 3-year analysis of the phase III COMBI-d study, with baseline site of metastasis identified as a predictor of overall survival ≥36 months,

Expert Highlights Resistance to Targeted Therapies, Role of Epigenetic Changes in Melanoma

November 8th 2016

Helmut Schiader, MD, discusses why drug resistance may be due to epigenetic changes and not mutation-induced changes, as well as the role of immunotherapy/targeted therapy combinations in combating resistance.

Immunotherapy Potentially Promising for Treatment of ATC

October 21st 2016

Given the poor prognoses often seen in patients with anaplastic thyroid cancer, researchers are seeking novel therapies that may hold more promise than surgery or radiation.

Rizvi Recounts Recent Immunotherapy Advances in Lung Cancer

September 20th 2016

Naiyer Rizvi, MD, discusses pivotal clinical trials of immunotherapy agents for patients with lung cancer and expresses his optimism regarding the treatment for the field.

Excitement Continues to Build for Advances in Neuroendocrine Tumor Field

August 18th 2016

James C. Yao, MD, discusses developments in the field of neuroendocrine tumors.

USPSTF Updates CRC Screening Guideline

June 21st 2016

The United States Preventative Services Task Force recommends screening for colorectal cancer using traditional colonoscopy or one of 7 tests at various frequencies for all patients aged 50 to 75.

Nurse-Led Study Evaluates Safe Use of Nephrostomy Tube to Deliver Chemotherapy and Biotherapy

April 28th 2016

Researchers at the Rutgers Cancer Institute of New Jersey are testing the possibility of sending treatment drugs directly to the kidney in patients with upper urinary tract urothelial carcinoma.